Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2012-02-08 13:08:50
Reporting Period:
Filing Date:
Accepted Time:
2012-02-08 13:08:50
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
850693 Allergan Inc AGN Pharmaceutical Preparations (2834) 951622442
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1190644 S Douglas Ingram 2525 Dupont Drive
Irvine CA 92612
Evp And President, Eame No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-02-07 66,000 $41.24 89,814 No 4 M Direct
Common Stock Disposition 2012-02-07 66,000 $86.37 23,814 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2012-02-07 66,000 $0.00 66,000 $41.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-01-30 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,662 Indirect By 401(k) Trust
Common Stock 3,597 Indirect By Esop Trust
  1. The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $86.25 to $86.53, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  2. Includes shares acquired under the Allergan, Inc. Dividend Reinvestment Plan.
  3. Shares allocated to reporting person's SIP account as of reporting date.
  4. Shares allocated to the reporting person's ESOP account as of reporting date.
  5. The option becomes exercisable in four equal annual installments beginning January 30, 2005.